Velocity Clinical Research, Inc.

In late 2024, Velocity successfully delivered an entire Phase 4 vaccine trial — managing all site operations and participant enrollment. • 1,000 participants enrolled across 24 Velocity sites • 450 adolescent participants • >45% identified as people of color, exceeding national averages Learn more about how Velocity enrolls representative populations at speed and at scale: https://lnkd.in/g7En6sbT #VelocityAtScale #ClinicalTrials #PatientRecruitment

In a recent interview about technology and clinical trial sites with Sanofi's Patrick Nadolny on the SCDM Podcast, Paul Evans explained how the Velocity's CTO shadowed a site coordinator for just one visit in one trial and touched 20 different technology systems. How many of those were Velocity's? Two. The other 18 came from the Sponsor or the CRO. There is a huge amount of effort required to get people comfortable with each of those systems, leading to a huge training burden. And this is increasing. The idea that technology is making trials more efficient is, in many cases, a misconception. It's designed to help the back office system of the Sponsor but often fails to help the site. Watch the interview to see what Paul recommends to ease the burden on sites and improve outcomes for patients.

Snehal Sampat will present at Advarra’s Onsemble 2025 conference in Orlando, FL! While sites often rely on valuable relationships with repeat participants, such recruitment sources have limited scalability. In this presentation, Snehal will explore how sites can take the lead in recruitment planning and execution by leveraging technology to support a multi-source approach. The session will also demonstrate how aligning incentives and integrating data between sites and recruitment vendors can generate higher-quality leads, streamline the participant experience, and provide the flexibility to adjust priorities in real time. If you’ll be in Orlando for #Onsemble, add this session to your calendar: Optimizing Patient Enrollment at Scale Via a Tech-Enabled Recruitment Model 📅 Tuesday, April 29, 2025 | 2 to 2:50 p.m. ET

Nadege Gunn, MD, CPI, DABOM, FAASLD, has been named a Fellow of the American Association for the Study of Liver Diseases (AASLD)! This designation is the highest honor awarded to AASLD members and recognizes Dr. Gunn’s exceptional contributions to liver disease research and clinical care. In addition to her impact on the broader research community, Dr. Gunn leads Velocity’s MASH CARE Council and plays a key role in advancing best practices in obesity-related clinical trials across Velocity sites worldwide. Congratulations on this well-deserved recognition, Dr. Gunn! #MASHCARE #ClinicalTrials

Velocity was selected to deliver all sites and participants for a recent Phase 4 clinical trial. The trial required adolescents and young adults with a specific vaccination status. While no formal demographic objectives were set for the trial, >45% of the 1,000 participants enrolled identified as people of color — surpassing the U.S. average. Read more about this study and others: https://lnkd.in/g7En6sbT #VelocityAtScale #ClinicalTrials

The UK has steadily lost its share of global clinical trials activity. In this article, Rachael Buck, Ph.D, highlights the challenges facing the UK's clinical trials sector, notably delays and resource constraints within the NHS. While recent government investments, such as the establishment of Commercial Research Delivery Centres (CRDCs), are positive steps, relying solely on NHS infrastructure overlooks existing, agile private clinical trial organizations. Can greater use of these private networks swiftly restore the UK's competitiveness in clinical research? Read the full article to learn more: https://lnkd.in/gaBGxQ9w #ClinicalTrials #UKLifeSciences #NHS

The rise of GLP-1 agonists has driven rapid growth in clinical development for obesity drugs. Research sites must keep pace. Our latest whitepaper explores obesity research from several site-based perspectives, with contributions from: • Brandon Essink, MD, CPI, Chief Physician Officer • Nadege Gunn, MD, CPI, DABOM, Medical Director, Waco, TX • Sarah Smiley, DO, FACP Medical Director, Medford, OR • Barbara Connor, MD, DABOM Principal Investigator, Syracuse, NY • Melinda Auxier, DO, Principal Investigator, Gulfport, MS • Raghu Punnamraju, Chief Technology Officer • Christy Godwin, SVP, Strategic Partnerships While there is significant interest in obesity drugs from both developers and potential participants, that interest doesn’t always translate to straightforward recruitment and trial conduct. As Dr. Gunn notes in this paper, “[Obesity trials] load up quickly, but the placebo effect can cause barriers to retention over time, which is why we work together to create realistic mitigation strategies.” Read the white paper below for more insights, and connect with Christy Godwin to discuss your next obesity trial. #Obesity #GLP1 #ClinicalTrials

Charles H Eger M.D., contributed to new research on a combination vaccine intended to provide protection against both seasonal flu and COVID-19 in a single shot. Early results from the Phase 1/2 trial show that the vaccine is well-tolerated and induces strong immune responses, potentially paving the way for a more convenient approach to respiratory virus prevention. Full article: https://lnkd.in/gAJMZcqg #mRNA #Vaccines #ClinicalTrials

Site efficiency impacts clinical trial timelines before the first participant is enrolled. By leveraging centralized operations, standardized workflows, and a dedicated regulatory team, Velocity achieves IRB review cycles that are 50% faster than industry peers. This includes time for submission, clarification, and approval. Each day counts. Faster approvals mean accelerated startup, quicker enrollment, and, ultimately, more timely commercialization of critical therapies. Learn more and explore recent case studies: https://lnkd.in/g7En6sbT #VelocityAtScale #ClinicalTrials

In this month's edition, Craig Koch shares his vision as our new EVP, General Manager of Europe, leading Velocity's expansion across Germany, Poland, and the U.K. Also featured: • Velocity is a finalist for a 2025 Vaccine Industry Excellence Award • New case study: 2,750+ randomizations (125% of goal) across 29 sites • Brandon Essink, MD, CPI publishes next-gen flu vaccine study results in Vaccine • Our Hyderabad team celebrates a new office expansion Tap or click below to read The Recap! #ClinicalTrials #ClinicalResearch